Alonso-Espinaco V, Marmol M, Alonso V, Escudero P, Horndler C, Ortego J, Gallego R, Garcia-Albeniz X, Jares P, Cuatrecasas M, Jose Lozano J, Castells A, Maurel J. Influence of BRAF mutations and RAC1b/RAC1 mRNA expression ratio on outcome in patients with metastatic colorectal cancer (mCRC) treated with first-line chemotherapy. Poster presented at the 2012 ASCO Annual Meeting; June 4, 2012. Chicago, IL. [abstract] J Clin Oncol. 2012 Jun; 30(15_Suppl):3553. doi: 10.1200/jco.2012.30.15_suppl.3553
Kiladjian J-J, Gisslinger H, Passamonti F, Niederwieser D, Mendelson E, Sirulnik LA, Copley-Merriman K, Zhou X, Levy RS, Knoops L, Cervantes F, Barbui T, Barosi G, Vannucchi AM, Harrison CN. Health-related quality of life (HRQoL) and symptom burden in patients (Pts) with myelofibrosis (MF) in the COMFORT-II study. Poster presented at the 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO); June 1, 2012. Chicago, IL. [abstract] J Clin Oncol. 2012 Jun 1; 30(15_suppl):6626. doi: 10.1200/jco.2012.30.15_suppl.6626
Davis KL, Gutierrez B, Zyczynski TM, Kaye JA. Treatment patterns in men with castration-resistant prostate cancer receiving docetaxel. J Clin Oncol. 2012 May 20;30(Suppl 15):e15165. doi: 10.1200/jco.2012.30.15_suppl.e15165
Hale KS, Wang H, Karanth S, Raber MN, Carlson HR, Lenzi R, Abbruzzese JL, Mills GB, Varadhachary GR. Mutation profiling in patients with carcinoma of unknown primary using the Sequenom MassARRAY System. Poster presented at the 2012 ASCO Annual Meeting I; June 2012. [abstract] J Clin Oncol. 2012 May 20; 30(15):4131. doi: 10.1200/jco.2012.30.15_suppl.4131
Goyal RK, Meyer AM, Sheets NC, Federspiel JJ, Carpenter WR, Chen RC, Biddle AK. Cost-utility of proton therapy in the treatment of localized prostate cancer. Poster presented at the 2012 ASCO Annual Meeting I; June 2012. Chicago, IL. [abstract] J Clin Oncol. 2012 May 20; 30(15):e15184.
Herring WL, Herrmann JW. The single-day surgery scheduling problem: sequential decision-making and threshold-based heuristics. OR spectrum: quantitative approaches in management. 2012 Apr 1;34(2):429-59.
Keiser J, Nakakura EK, Imhoff L, Mayorga M, Bobiak S, Venook AP, Bergsland EK. Incidence and natural history of bone metastases in neuroendocrine tumors. Poster presented at the 2012 Gastrointestinal Cancers Symposium; February 1, 2012. San Francisco, CA. [abstract] J Clin Oncol. 2012 Feb 1; 30(Number 4_suppl):340. doi: 10.1200/jco.2012.30.4_suppl.340
Choti MA, Mayorga MA, Bobiak S, Kulke M, Yao JC, Bergsland EK, Nakakura EK, Bloomston M, Benson AB, Shah MH, Strosberg JR. Baseline demographics of patients with neuroendocrine tumors presenting to seven national comprehensive cancer network (NCCN) institutions: development of a multi-institutional outcomes database. Poster presented at the 2012 Gastrointestinal Cancers Symposium; February 1, 2012. [abstract] J Clin Oncol. 2012 Feb 1; 30(Number 4_suppl):187. doi: 10.1200/jco.2012.30.4_suppl.187